Side Effects of quizartinib: A Synthesis of Findings from 3 Studies

  1. Home
  2. Side Effects of quizartinib
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of quizartinib: A Synthesis of Findings from 3 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of quizartinib: A Synthesis of Findings from 3 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Quizartinib is an effective treatment for patients with FLT3-ITD acute myeloid leukemia (AML) by inhibiting the activity of the FLT3 gene, which leads to the death of cancer cells. 3 Multiple clinical trials have shown its effectiveness in patients with relapsed or refractory AML with an FLT3-ITD mutation. 3

Nilotinib, a tyrosine kinase inhibitor used for the treatment of chronic myelogenous leukemia (CML), has been associated with the development of squamous cell carcinomas (SCCs). 1

Gold nanoparticles conjugated with FLT3 inhibitors are being investigated as potential therapeutic agents for the treatment of AML. 2 These conjugates have the potential to deliver drugs specifically to the tumor site, minimizing systemic damage and side effects. 2

Reasons for side effects

Quizartinib inhibits the activity of the FLT3 gene, which can lead to the inhibition of downstream pathways including RAS/RAF/MEK, MAPK/ERK, PI3K/AKT/mTOR, and JAK/STAT5 signaling pathways. 3

Common side effects

Quizartinib

Quizartinib can inhibit downstream pathways including RAS/RAF/MEK, MAPK/ERK, PI3K/AKT/mTOR, and JAK/STAT5 signaling pathways by inhibiting the activity of the FLT3 gene. 3

Nilotinib

Nilotinib has been associated with the development of squamous cell carcinomas (SCCs). 1

Side effect management

Quizartinib

Further research is needed to find ways to reduce the toxicity of quizartinib. 3

Nilotinib

Patients taking nilotinib should be closely monitored by a dermatologist for any signs of skin abnormalities. 1

Comparison between studies

Commonalities

All three studies focus on targeted therapies for cancer treatment.

Differences

The three studies investigate different types of cancer. Quizartinib is being researched as a treatment for AML. 3 Nilotinib is being researched as a treatment for CML. 1 Gold nanoparticles conjugated with FLT3 inhibitors are being investigated as potential therapeutic agents for the treatment of AML. 2

Practical implications and precautions

Quizartinib shows promise as a treatment for AML patients with the FLT3-ITD mutation, but further research is needed. 3 Patients taking nilotinib should be closely monitored by a dermatologist. 1

Limitations of current research

Larger clinical trials are needed to verify the safety and efficacy of quizartinib. 3 Clinical trials are also needed to assess the effectiveness of quizartinib in combination with chemotherapy or allogeneic hematopoietic cell transplantation. 3

Future research directions

Further research is needed to develop strategies to reduce the side effects of quizartinib. 3

Conclusion

Quizartinib is a promising treatment option for AML patients with the FLT3-ITD mutation. 3 However, further research is needed, especially regarding side effect management. 3 Nilotinib is an effective tyrosine kinase inhibitor for the treatment of CML but can cause the development of squamous cell carcinomas. 1 Patients taking nilotinib should be closely monitored by a dermatologist. 1

Literature analysis of 3 papers
Positive Content
3
Neutral Content
0
Negative Content
0
Article Type
0
0
0
1
3
1.

Eruption of squamous cell carcinomas after beginning nilotinib therapy.

Author: CrainCaroline B, WinsettFrank T, WoolridgeKatelyn F, WilsonJanice M, GoodwinBrandon P

CML treatment
SCC development

This case report describes a patient with chronic myelogenous leukemia who developed multiple squamous cell carcinomas (SCCs) after beginning treatment with nilotinib, a tyrosine kinase inhibitor. The authors highlight the potential for nilotinib to cause eruptive SCCs and recommend close monitoring by a dermatologist.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

3.

Quizartinib (AC220): a promising option for acute myeloid leukemia.

Author: ZhouFang, GeZheng, ChenBaoan

AML treatment

Quizartinib is an effective therapy for patients with FLT3-ITD acute myeloid leukemia (AML) by inhibiting the activity of the FLT3 gene. This review summarizes the characteristics of FLT3/ITD mutations, the mechanism and pharmacokinetics of quizartinib, and the mechanisms of resistance to the drug. The review also discusses clinical experiences and adverse effects associated with quizartinib.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.